FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1363-1373 September 29, 2005 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

The impact of influenza infection is felt globally each year when the disease develops in approximately 20 percent of the world's population. In the United States, influenza infections occur in epidemics each winter, generally between late December and early March. Recent events, including human cases of avian influenza, have heightened awareness of the threat of a pandemic and have spurred efforts to develop plans for its control.

Although vaccination is the primary strategy for the prevention of influenza, there are a number of likely scenarios for which vaccination is inadequate and effective antiviral agents would be of the utmost importance. . . . [Full Text of this Article]

Adamantanes and Neuraminidase Inhibitors

Development of Neuraminidase Inhibitor Molecules

Pharmacokinetics

Clinical Trials of Zanamivir and Oseltamivir

Treatment of Healthy Adults

Therapy in the Elderly

Therapy in Children

Prophylactic Efficacy of Zanamivir and Oseltamivir

Prophylaxis in Healthy Adults

Prophylaxis in High-Risk Elderly or Chronically Ill Populations

Prophylaxis in Children after Exposure

Safety and Dosage of Neuraminidase Inhibitors

Resistance to the Neuraminidase Inhibitors

Strategies for Treatment

Strategies for Prophylaxis

Avian Influenza and Pandemic Planning

Source Information

From the Departments of Pediatrics and Microbiology and Immunology, Weill Medical College of Cornell University, New York.

Address reprint requests to Dr. Moscona at the Department of Pediatrics, Box 309, Weill Medical College of Cornell University, 515 E. 71st St., Suite 600D, New York, NY 10021, or at anm2047@med.cornell.edu.

This article has been cited by other articles:

• Sym, D., Patel, P. N, El-Chaar, G. M (2009). Seasonal, Avian, and Novel H1N1 Influenza: Prevention and Treatment Modalities. The Annals of Pharmacotherapy 43: 2001-2011 [Abstract] [Full Text]  
• Hoffmann, G., Funk, C., Fowler, S., Otteneder, M. B., Breidenbach, A., Rayner, C. R., Chu, T., Prinssen, E. P. (2009). Nonclinical Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in the Central Nervous System. Antimicrob. Agents Chemother. 53: 4753-4761 [Abstract] [Full Text]  
• Khazeni, N., Bravata, D. M., Holty, J.-E. C., Uyeki, T. M., Stave, C. D., Gould, M. K. (2009). Systematic Review: Safety and Efficacy of Extended-Duration Antiviral Chemoprophylaxis Against Pandemic and Seasonal Influenza. ANN INTERN MED 151: 464-473 [Abstract] [Full Text]  
• McSharry, J. J., Weng, Q., Brown, A., Kulawy, R., Drusano, G. L. (2009). Prediction of the Pharmacodynamically Linked Variable of Oseltamivir Carboxylate for Influenza A Virus Using an In Vitro Hollow-Fiber Infection Model System. Antimicrob. Agents Chemother. 53: 2375-2381 [Abstract] [Full Text]  
• Laplante, J. M., Marshall, S. A., Shudt, M., Van, T. T., Reisdorf, E. S., Mingle, L. A., Shult, P. A., St. George, K. (2009). Influenza Antiviral Resistance Testing in New York and Wisconsin, 2006 to 2008: Methodology and Surveillance Data. J. Clin. Microbiol. 47: 1372-1378 [Abstract] [Full Text]  
• Dharan, N. J., Gubareva, L. V., Meyer, J. J., Okomo-Adhiambo, M., McClinton, R. C., Marshall, S. A., St. George, K., Epperson, S., Brammer, L., Klimov, A. I., Bresee, J. S., Fry, A. M., for the Oseltamivir-Resistance Working Group, (2009). Infections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States. JAMA 301: 1034-1041 [Abstract] [Full Text]  
• Deyde, V. M., Nguyen, T., Bright, R. A., Balish, A., Shu, B., Lindstrom, S., Klimov, A. I., Gubareva, L. V. (2009). Detection of Molecular Markers of Antiviral Resistance in Influenza A (H5N1) Viruses Using a Pyrosequencing Method. Antimicrob. Agents Chemother. 53: 1039-1047 [Abstract] [Full Text]  
• Gabbard, J., Velappan, N., Di Niro, R., Schmidt, J., Jones, C.A., Tompkins, S.M., Bradbury, A.R.M. (2009). A humanized anti-M2 scFv shows protective in vitro activity against influenza. Protein Eng Des Sel 22: 189-198 [Abstract] [Full Text]  
• Casscells, S. W., Granger, E., Kress, A. M., Linton, A., Madjid, M., Cottrell, L. (2009). Use of Oseltamivir After Influenza Infection Is Associated With Reduced Incidence of Recurrent Adverse Cardiovascular Outcomes Among Military Health System Beneficiaries With Prior Cardiovascular Diseases. Circ Cardiovasc Qual Outcomes 2: 108-115 [Abstract] [Full Text]  
• Jhee, S. S., Yen, M., Ereshefsky, L., Leibowitz, M., Schulte, M., Kaeser, B., Boak, L., Patel, A., Hoffmann, G., Prinssen, E. P., Rayner, C. R. (2008). Low Penetration of Oseltamivir and Its Carboxylate into Cerebrospinal Fluid in Healthy Japanese and Caucasian Volunteers. Antimicrob. Agents Chemother. 52: 3687-3693 [Abstract] [Full Text]  
• Sheu, T. G., Deyde, V. M., Okomo-Adhiambo, M., Garten, R. J., Xu, X., Bright, R. A., Butler, E. N., Wallis, T. R., Klimov, A. I., Gubareva, L. V. (2008). Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52: 3284-3292 [Abstract] [Full Text]  
• Zeng, Q., Langereis, M. A., van Vliet, A. L. W., Huizinga, E. G., de Groot, R. J. (2008). Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution. Proc. Natl. Acad. Sci. USA 105: 9065-9069 [Abstract] [Full Text]  
• Huang, I-C., Li, W., Sui, J., Marasco, W., Choe, H., Farzan, M. (2008). Influenza A Virus Neuraminidase Limits Viral Superinfection. J. Virol. 82: 4834-4843 [Abstract] [Full Text]  
• Nicoll, A (2008). Children, avian influenza H5N1 and preparing for the next pandemic. Arch. Dis. Child. 93: 433-438 [Abstract] [Full Text]  
• Carter, M. J. (2007). A rationale for using steroids in the treatment of severe cases of H5N1 avian influenza. J Med Microbiol 56: 875-883 [Abstract] [Full Text]  
• Nuno, M, Chowell, G, Gumel, A.B (2007). Assessing the role of basic control measures, antivirals and vaccine in curtailing pandemic influenza: scenarios for the US, UK and the Netherlands. J R Soc Interface 4: 505-521 [Abstract] [Full Text]  
• Hatakeyama, S., Sugaya, N., Ito, M., Yamazaki, M., Ichikawa, M., Kimura, K., Kiso, M., Shimizu, H., Kawakami, C., Koike, K., Mitamura, K., Kawaoka, Y. (2007). Emergence of Influenza B Viruses With Reduced Sensitivity to Neuraminidase Inhibitors. JAMA 297: 1435-1442 [Abstract] [Full Text]  
• Moscona, A., McKimm-Breschkin, J. (2007). News About Influenza B Drug Resistance That Cannot Be Ignored. JAMA 297: 1492-1493 [Full Text]  
• Skowronski, D. M., Li, Y., Tweed, S. A., Tam, T. W.S., Petric, M., David, S. T., Marra, F., Bastien, N., Lee, S. W., Krajden, M., Brunham, R. C. (2007). Protective measures and human antibody response during an avian influenza H7N3 outbreak in poultry in British Columbia, Canada. CMAJ 176: 47-53 [Abstract] [Full Text]  
• Rameix-Welti, M. A., Agou, F., Buchy, P., Mardy, S., Aubin, J. T., Veron, M., van der Werf, S., Naffakh, N. (2006). Natural Variation Can Significantly Alter the Sensitivity of Influenza A (H5N1) Viruses to Oseltamivir. Antimicrob. Agents Chemother. 50: 3809-3815 [Abstract] [Full Text]  
• Ge, Q., Pastey, M., Kobasa, D., Puthavathana, P., Lupfer, C., Bestwick, R. K., Iversen, P. L., Chen, J., Stein, D. A. (2006). Inhibition of Multiple Subtypes of Influenza A Virus in Cell Cultures with Morpholino Oligomers. Antimicrob. Agents Chemother. 50: 3724-3733 [Abstract] [Full Text]  
• Gillim-Ross, L., Subbarao, K. (2006). Emerging Respiratory Viruses: Challenges and Vaccine Strategies. Clin. Microbiol. Rev. 19: 614-636 [Abstract] [Full Text]  
• Singh, A M, Busse, W W (2006). Asthma exacerbations {middle dot} 2: Aetiology. Thorax 61: 809-816 [Abstract] [Full Text]  
• Bartlett, J. G. (2006). Planning for Avian Influenza. ANN INTERN MED 145: 141-144 [Abstract] [Full Text]  
• Regoes, R. R., Bonhoeffer, S. (2006). Emergence of drug-resistant influenza virus: population dynamical considerations.. Science 312: 389-391 [Abstract] [Full Text]  
• Germann, T. C., Kadau, K., Longini, I. M. Jr., Macken, C. A. (2006). From the Cover: Mitigation strategies for pandemic influenza in the United States. Proc. Natl. Acad. Sci. USA 103: 5935-5940 [Abstract] [Full Text]  
• (2006). High Levels of Adamantane Resistance Among Influenza A (H3N2) Viruses and Interim Guidelines for Use of Antiviral Agents--United States, 2005-06 Influenza Season. JAMA 295: 881-882 [Full Text]  
• Weinstock, D. M., Zuccotti, G. (2006). Adamantane Resistance in Influenza A. JAMA 295: 934-936 [Full Text]  
• Gostin, L. O. (2006). Medical Countermeasures for Pandemic Influenza: Ethics and the Law. JAMA 295: 554-556 [Full Text]  
• Moscona, A. (2005). Oseltamivir Resistance -- Disabling Our Influenza Defenses. NEJM 353: 2633-2636 [Full Text]  
• de Jong, M. D., Thanh, T. T., Khanh, T. H., Hien, V. M., Smith, G. J.D., Chau, N. V., Cam, B. V., Qui, P. T., Ha, D. Q., Guan, Y., Peiris, J.S. M., Hien, T. T., Farrar, J. (2005). Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection. NEJM 353: 2667-2672 [Abstract] [Full Text]  
• Tanne, J. H. (2005). Roche considers licensing companies to make oseltamivir. BMJ 331: 981-981 [Full Text]  
• Macfarlane, J. T, Lim, W. S. (2005). Bird flu and pandemic flu. BMJ 331: 975-976 [Full Text]